Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis

Files

Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis.pdf (268.29 KB)

Date

2017

Type:

Artículo

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

189

Vistas totales

4
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

John Wiley & Sons

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

URI

http://hdl.handle.net/11447/1703
 http://dx.doi.org/10.1002/alr.21910

item.page.extent

6

item.page.accessRights

item.page.other

item.page.references

Abstract

BACKGROUND: Although short-term use (≤2 months) of atomized topical nasal steroids has been shown to be safe and effective, the long-term safety has yet to be demonstrated. The aim of this study was...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Manji J, Singh G, Okpaleke C, Dadgostar A, Al-Asousi F, Amanian A, Macias-Valle L, Finkelstein A, Tacey M, Thamboo A, Javer A. Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017 May;7(5):488-493. doi: 10.1002/alr.21910

Keywords

HPA axis , IOP , budesonide , chronic rhinosinusitis , mucosal atomization device , postoperative care , safety

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
2 1,5 1 0,5 0
Agosto 2025Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026

Implementado por OpenGeek Services